Teva begins cuts at NY plant it expects to shutter by early next year


Israel-based Teva Pharmaceuticals ($TEVA) has begun letting staff go at its Pomona site in Haverstraw, NY, that the company expects to close by February. That facility produces niacin, which is used to treat cholesterol and triglyceride levels.

The company notified about 80 of the 236 people working at the plant earlier this week.

“Closure of the Pomona site has been under consideration for a period of time,” company spokeswoman Michele Pelkowski, a company spokeswoman told The Journal News of the Lower Hudson Valley. “And Teva’s Pomona-based employees were informed previously of this possibility.”

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Teva acquired the plant, which also has some R&D operations at the site, in 2008 when it purchased Barr Pharmaceuticals. The company has previously said it planned to consolidate its R&D operations in Elizabeth, NJ. Teva also has New York operations in Fairfield, Buffalo, and Coplague.

R&D workers in Haverstraw are expected to be offered a chance to interview for jobs in New Jersey.

Teva completed its nearly $40 billion deal for generic drug maker Allergan ($AGN) in early August. The company has since said it wants throw an additional $500 million into the acquisition to buy Allergan’s supply chain operation Anda, the fourth largest drug distributor in the U.S.

- check out The Journal News story

Read more:
Teva wants Allergan's distribution biz now that $40B drug deal has closed 
With Allergan deal sealed, Teva turns its attention to branded M&A 
McKesson extends its Canada supply chain reach with $2.23B deal for Rexall chain 
Drug distributor McKesson laying off 1,600 
AmerisourceBergen lays out $2.5B for sterile compounder PharMEDium

Suggested Articles

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.

The FDA has slapped a warning letter on an Indian solvent recycler that may have contributed to the contamination of blood pressure meds.